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Abstract
Treponema pallidum, herpes simplex virus types 1 or 2 (HSV-1/2) and Haemophilus ducreyi are sexually transmitted pathogens that can cause
genital, anal and oropharyngeal ulcers. Laboratory evaluation of these pathogens in ulcers requires different types of specimens and tests,
increasing the risk of improper specimen handling and time lapse until analysis. We sought to develop a new real-time PCR (TP-HD-HSV1/2
PCR) to facilitate the detection of T. pallidum, HSV-1/2 and H. ducreyi in ulcers. The TP-HD-HSV1/2 PCR was tested (i) in a retrospective
study on 193 specimens of various clinical origin and (ii) in a prospective study on 36 patients with genital, anal or oropharyngeal ulcers
(ClinicalTrials.gov # NCT01688258). The results of the TP-HD-HSV1/2 PCR were compared with standard diagnostic methods (T. pallidum:
serology, dark field microscopy; HSV-1/2: PCR; H. ducreyi: cultivation). Sensitivity and specificity of the TP-HD-HSV1/2 PCR for T. pallidum
were both 100%, for HSV-1 100% and 98%, and for HSV-2 100% and 98%, respectively. T. pallidum and HSV-1/2 were detected in 53% and
22% of patients in the prospective study; H. ducreyi was not detected. In the prospective study, 5/19 (26%) specimens were true positive for
T. pallidum in the TP-HD-HSV1/2 PCR but non-reactive in the VDRL. The TP-HD-HSV1/2 PCR is sensitive and specific for the detection of
T. pallidum and HSV-1/2 in routine clinical practice and it appears superior to serology in early T. pallidum infections.
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Introduction
Treponema pallidum, herpes simplex virus types 1 or 2 (HSV-1/
2) and Haemophilus ducreyi are, worldwide, the most common
sexually transmitted pathogens that cause ulcers of the genital,
anal and oropharyngeal region [1,2]. The global annual
incidence of ulcers caused by sexually transmitted infections
is 20 million cases [3], and genital ulcers are a significant risk
factor for transmission and acquisition of human immunode-
ficiency virus (HIV). Identification of ulcer-causing pathogens is
a prerequisite for an effective therapy and reducing the risk of
HIV infection [4], but is unreliable based on clinical presen-
tation due to pleomorphic clinical presentation and mixed
infections [1,5,6]. Hence, laboratory methods are indispens-
able for substantiating the diagnosis. Currently, the most
widely used standard methods (‘reference methods’) for the
diagnosis of T. pallidum infection are serology and dark field
microscopy [7,8]; for HSV-1/2 infection these are PCR,
cultivation, serology and direct immunofluorescence (DIF)
[8–10]; for H. ducreyi infection it is cultivation [8].
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
However, these methods have limitations. For example,
T. pallidum serology has a low sensitivity in early syphilis when
ulcers occur [11]. Dark field microscopy is prone to improper
specimen collection and handling, dark field microscopes are
not widely available, evaluation requires an experienced
observer, and this method is not applicable for oral specimens
[12,13]. For the detection of HSV-1/2, PCR has increased the
diagnostic sensitivity by almost 70% compared with cultivation
[8,9]. The laborious and poorly sensitive HSV cultivation needs
7–10 days to exclude an infection, and sensitivity and specificity
of serology are insufficient during early infection [14]. H. duc-
reyi is a fastidious pathogen and cultivation has a sensitivity of
<80% and is not suitable for routine clinical practice [15]. As a
consequence, laboratory evaluation of genital ulcers requires
the collection of various specimen types and the coordinated
distribution to different laboratories, increasing the risk of
improper specimen handling and time lapse until analysis. This
may have implications for sensitivity, and may delay the
diagnosis and specific treatment. To overcome these difficul-
ties, we developed a new real-time PCR (TP-HD-HSV1/2 PCR)
for the diagnosis of T. pallidum, HSV 1/2 and H. ducreyi
(TP-HD-HSV1/2 PCR) in genital, anal and oropharyngeal
ulcers. Nylon flocked swabs were used to collect specimens
from the ulcer base, which is an appropriate method for
detecting T. pallidum, HSV-1/2 and H. ducreyi by PCR [16,17].
We sought to investigate (i) the sensitivity, specificity and
clinical applicability of the TP-HD-HSV1/2 PCR and (ii) the rate
of pathogens and clinical characteristics in patients with ulcers
in a prospective clinical study. This study was designed and
performed according guidelines for the evaluation and report-
ing of new diagnostic tests [18,19].
Materials and Methods
TP-HD-HSV1/2 PCR
New primers and probes targeting the 16S rRNA gene were
designed for T. pallidum and H. ducreyi (Table 1). Oligos were
designed with Primer3 (v. 0.4.0) [20] based on GenBank
sequences M88726.1 (T. pallidum) and M75078.1 (H. ducreyi)
and commercially synthesized (Microsynth AG, Balgach, Swit-
zerland). HSV-1/2 specific oligos have been described previ-
ously [21]. Optimal reaction conditions were assessed by
amplification of tenfold dilutions of DNA with increasing
annealing temperature from 50 to 66°C. DNA from T. pallidum
was extracted from rabbit testis homogenate with the DNeasy
tissue kit (Qiagen, Hilden, Germany) and provided by
Euroimmun AG (Lu¨beck, Germany), HSV-1/2 DNA was
provided by Professor Werner Kempf (Zurich, Switzerland),
and H. ducreyi DNA was isolated from strain CIP 100296
(CRBIP, Institute Louis Pasteur, Paris, France). Prior tenfold
dilutions, the concentrations of genomic DNA stock were
determined with a Nanodrop 1000 spectrophotometer
(Thermo Fisher Scientific, Wohlen, Switzerland) and were as
follows (average of three measurements): T. pallidum, 30.7 ng/
lL; HSV-1, 7.9 ng/lL; HSV-2, 10.4 ng/lL; H. ducreyi 44.9 ng/
lL. Species identity of amplicons was confirmed by sequencing
(Microsynth AG).
For DNA extraction, 0.5 mL of swab eluat was spinned at
20 000 9 g for 10 min. The pellet was incubated with 40 lg
proteinase K (Roche Diagnostics, Rotkreuz, Switzerland) for
2 h at 54°C on a shaking incubator. Proteinase K was
inactivated for 10 min at 94°C, detritus was pelleted at
20 000 9 g for 10 min at room temperature and the
DNA-containing supernatant was stored at 20°C until
amplification.
PCR was performed with a Roche LightCycler 2.0 (Roche
Diagnostics). The assay was split into two reactions (i.e. tube 1
for detecting T. pallidum and the internal control (inhibition
control) and tube 2 for H. ducreyi, HSV-1 and HSV-2). The
20-lL reaction volume contained 4 lL 5 9 LightCycler Taq-
Man mastermix (Roche), 0.25 lL LightCycler Uracil-DNA
Glycosylase, 0.5 lM of each primer, 0.1 lM probe, 1 lL
internal control (only in tube 1) and 5 lL extracted DNA.
Reaction conditions were: activation of uracil-N-glucosylase at
40°C for 10 min, pre-denaturation at 95°C for 10 min, 45
cycles of denaturation at 95°C for 10 s and annealing/
amplification at 66°C for 1 min. A colour compensation
according to the LightCycler 2.0 manufacturer’s instructions
was performed and used for valid interpretation of results.
TABLE 1. Primers and probes used in the new real-time
multiplex PCR
Namea Sequence Tmb
Treponema pallidumc
TP-Zh-131-f GCCTTTGAGATGGGGATAGC 59.2
TP-Zh-245-r GTCGCAGGCTCATCTCTGA 58.9
TP-Zh-220-p FAM-CCGCAGCCCCTTTCCT
CTCA-BHQ-1
67.9
Internal control
IC-Zh-p Yakima Yellow-TCGTGCCTCA
GTGCCAGTCAC-BHQ-1
66.3
Haemophilus ducreyid
HD-Zh-992-f ACATCCATAGAAGAACTCAGAGATGA 60.3
HD-Zh-1150-r TTGAGTTCCCATCAYTACATGCT 59.9
HD-Zh-1022-p Yakima Yellow-GTGCCTTCGGGAA
CTATGTGACAGGT-BHQ-1
67.6
Herpes simplex 1/2e
GbTypF CGCATCAAGACCACCTCCTC 60.3
GbTypR GCTCGCACCACGCGA 55.2
GbTyp1 FAM-TGGCAACGCGGCCCAAC-BHQ-1 60.2
GbTyp2 ROX-CGGCGATGCGCCCCAG-BHQ-2 60.8
Tm, melting temperature.
aNumbers refer to the oligo 50 start position in the target sequence; f indicates
forward primer; p, probe; r, reverse primer.
bAverage of 4 Tm calculators (Primer3, Microsynth, OligoCalc and Oligo Analyzer)
in degrees Celsius.
cTarget gene was the bacterial 16S ribosomal RNA gene, GenBank M88726.1.
dTarget gene was the bacterial 16S ribosomal RNA gene, GenBank M75078.1.
eCorey et al. [21].
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Testing for analytical sensitivity and specificity
Analytical sensitivity was determined with serial dilutions of
pathogen-specific DNA fragments synthesized in pUC57
plasmids (GenScript, Piscataway, NJ, USA). The internal
control (inhibition control) was based on the T. pallidum
target sequence with a unique probe-binding region. Serial
dilutions of plasmid DNA were analysed in three independent
runs. Although being a commonly used method, the DNA copy
numbers determined by PCR may differ between plasmid vs.
chromosomally encoded sequences such as the pathogen-spe-
cific sequences targeted in this study [22]. Also, inhibitory
compounds present in clinical specimens such as lactoferrin or
haemoglobin [23] may alter the PCR kinetics compared with
the use of recombinant plasmid DNA.
Analytical specificity was confirmed (i) against published
DNA sequences of human, bacterial or viral origin with the
NCBI BLASTN algorithm (query database: ‘nucleotide collec-
tion’) and with Primer BLAST (query database: ‘nr’ with no
restriction to organisms) [24], (ii) by sequencing the amplicons
for each pathogen, and (iii) by assessing possible cross-reac-
tions of primers and probes with human DNA and inhibitory
effects of human DNA on the PCR reaction.
Testing for clinical sensitivity and specificity
We tested two panels of specimens from genital, anal or
oropharyngeal ulcers with the new TP-HD-HSV1/2 PCR.
1. The retrospective study comprised: (i) 115 DNA extracts from
clinical specimens (25 cervical swabs, 25 urethral swabs, 11
vulva swabs, four penis swabs, two ulcer swabs, nine blister
swabs, one anal swab, one vaginal swab, 11 respiratory tract
swabs, 10 faeces samples and 16 urine samples), which were
collected at Bioanalytica AG, Lucerne, Switzerland; these
samples originated mainly from patients with urogenital
disorders and a few with respiratory or gastrointestinal
disorders and were chosen in order to assess the specificity;
(ii) 18 DNA extracts from genital ulcer swabs; and (iii) 60
swab eluates from genital ulcer swabs (cotton swabs in
phosphate-buffered saline collected at the Public Health
Laboratory in Amsterdam, the Netherlands).
2. The prospective clinical study comprised swabs from patients
with genital, anal or oropharyngeal ulcers. The study was
approved by the ethics committees in Zurich, Switzerland,
and Graz, Austria (ClinicalTrials.gov # NCT01688258).
Patients were recruited at outpatient clinics in Switzerland
(Department of Dermatology, University Hospital Zurich;
Division of Infectious Diseases, University Hospital Zurich;
Division of Dermatology, City Hospital Triemli, Zurich;) and
Austria (Department of Dermatology and Venereology,
Medical University of Graz). All patients gave written
informed consent and were seen by a board-certified
dermatologist or infectious diseases specialist at enrollment.
Inclusion criteria were (i) presence of genital, anal or
oropharyngeal ulcers, (ii) patient’s age ≥18 years, and (iii)
written informed consent. Exclusion criteria were systemic
or topical antibiotic therapy within 2 weeks before enroll-
ment. Clinical specimens for the TP-HD-HSV1/2 PCR were
taken from the ulcer base with nylon flocked swabs (eSwabs;
Copan Diagnostics, Brescia, Italy) and stored at 20°C until
DNA extraction and PCR at the Department of Dermatol-
ogy, University Hospital Zurich. A case report form with
clinical metadata was available for each patient.
Comparative diagnostics with reference methods
In the retrospective panel, a reference PCR was performed in
78/193 specimens (40%) for T. pallidum [25] and in 104/193
(54%) for HSV-1/2 [26,27]. H. ducreyi was not tested. Speci-
mens not tested by reference PCR were assumed to be
negative. In the prospective study, the results of the
TP-HD-HSV1/2 PCR were compared with the following
reference methods: for T. pallidum dark field microscopy and
syphilis serology as previously described [11]; for HSV-1/2 a
validated routine PCR (Institute of Medical Virology, University
of Zurich; Molecular Biology, Department of Dermatology,
Medical University of Graz); and for H. ducreyi cultivation on
Chocolate II Agar (BD, Allschwil, Switzerland) and Muel-
ler-Hinton-Agar containing horse blood and IsoVitaleX and
GC Hemoglobin Agar containing calf serum and IsoVitaleX
[28].
In cases with discrepant results, samples were sent to a
reference laboratory in Amsterdam, the Netherlands (Public
Health Laboratory, GGD Amsterdam) for re-analysis. There, a
PCR specific for T. pallidum described by Koek et al. [25] or
HSV-1/2 described by van Doornum et al. [26] were used.
Both PCR assays were routinely used for the detection of the
respective pathogen in this reference laboratory.
Statistics
Statistical analysis was performed with R statistical software,
version 3.0.1 (Vienna, Austria) [29]. Sensitivity and specificity
of the new TP-HD-HSV1/2 PCR were computed with the
function ‘epi.tests’. The McNemar test (function ‘mcne-
mar.test’) was applied to assess differences between the
TP-HD-HSV1/2 PCR and reference methods. Continuous
variables were tested for parametric distribution by histo-
grams, quantile-quantile plots and the Shapiro test. Differences
between groups were tested with the Kruskal–Wallis rank
sum test, ANOVA or Fisher’s exact test where applicable. In
the case of a p value <0.05, a pairwise comparison between all
groups was computed with the Wilcoxon rank sum test,
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ANOVA or Fisher’s exact test where applicable. Adjustment
for multiple comparisons (n = 3) was computed with the
method of Benjamini and Hochberg (function ‘p.adjust’,
method = ‘fdr’) or TukeyHSD (function ‘TukeyHSD’) where
applicable.
Results
Analytical sensitivity and specificity of the TP-HD-HSV1/2
PCR
The sensitivity to detect a pathogen was NOT lower if DNA of
another pathogen was present in the reaction mix. Also,
human DNA was not detected by the TP-HD-HSV 1/2 PCR
and the presence of human DNA had no influence on the
sensitivity of the new PCR. The analytical sensitivity was ≤10
plasmid copies/reaction for T. pallidum and H. ducreyi, and ≤25
plasmid copies/reaction for the HSV assay.
Retrospective study
Results for T. pallidum were 100% concordant between the
TP-HD-HSV1/2 PCR and the reference T. pallidum-specific
PCR (Tables 2 and 3). In the TP-HD-HSV1/2 PCR, 2/193
reference samples (1%) were considered false-positive for
HSV-1 and 3/193 (2%) for HSV-2 (Table 2). These samples
were positive with high Ct values (range, 34.4–39.5 cycles),
indicating a very low amount of HSV-specific DNA supposedly
due to cross-contamination during DNA extraction. H. ducreyi
was not tested in the reference laboratories and no sample
was positive in the TP-HD-HSV1/2 PCR.
Prospective clinical study
Patients. From 36 patients with genital, anal or oropharyngeal
ulcers, 39 specimens were collected between July 2012 and
June 2013. According to reference methods, 17/36 patients
(47%) were infected with T. pallidum, 3/36 (8%) with HSV-1
and 4/36 (11%) with HSV-2. Upon discrepancy analyses, 19/36
patients (53%) had T. pallidum, and 4/36 patients (11%) each
had HSV-1 and HSV-2 (Table 4). One patient, a 64-year-old
man, had a co-infection with T. pallidum and HSV-2. H. ducreyi
was not detected by the reference method. Ten patients
(27.8%) had ulcers due to other reasons (Table 4): 2/10
patients (20%) had chancriform pyoderma, 1/10 (10%) had
candida balanitis and in 7/10 patients (70%) ulcers remained of
unknown origin. Multiple ulcers were present in 11/36 patients
(31%). Ulcers in the genital and oropharyngeal region were
present in 2/19 T. pallidum-positive patients (11%) and in 1/10
patients (10%) with ulcers due to other causes. Ulcers in the
genital, anal and oropharyngeal region were found in the
T. pallidum/HSV-2 co-infected patient.
Comparison between TP-HD-HSV1/2 PCR and reference method.
The TP-HD-HSV1/2 PCR was concordant in the 17 patients
who were T. pallidum positive by the reference methods and
TABLE 2. Comparison of the new multiplex real-time PCR with the reference PCR in the retrospective study using samples
from reference laboratories in the Netherlands and Switzerland
New real-
time PCR
Treponema palliduma Herpes simplex virus type 1b Herpes simplex virus type 2c
Reference method Reference method Reference method
Positive
No. (%)
Negative
No. (%)
Total
No. (%)
Positive
No. (%)
Negative
No. (%)
Total
No. (%)
Positive
No. (%)
Negative
No. (%)
Total
No. (%)
Positive 20 (100) 0 (0) 20 (10) 24 (100) 2 (1) 26 (13) 21 (100) 3 (2) 24 (12)
Negative 0 (0) 173 (100) 173 (90) 0 (0) 167 (99) 167 (87) 0 (0) 169 (98) 169 (88)
Total 20 (100) 173 (100) 193 (100) 24 (100) 169 (100) 193 (100) 21 (100) 172 (100) 193 (100)
aMcNemar test p 1.
bMcNemar test p 0.48.
cMcNemar test p 0.25.
TABLE 3. Sensitivity and specificity of the new real-time multiplex PCR compared with the reference methods in the
retrospective and the prospective clinical studies
Pathogen
Retrospective study Prospective clinical study Overall
Sensitivity,
% (95% CI)
Specificity,
% (95% CI)
Sensitivity,
% (95% CI)
Specificity,
% (95% CI)
Sensitivity,
% (95% CI)
Specificity,
% (95% CI)
Treponema pallidum 100 (76–100) 100 (97–100) 100 (78–100) 100 (73–100) 100 (88–100) 100 (97–100)
Herpes simplex type 1 100 (80–100) 99 (96–100) 100 (28–100) 96 (79–99) 100 (82–100) 98 (96–100)
Herpes simplex type 2 100 (77–100) 98 (95–100) 100 (36–100) 100 (79–100) 100 (77–100) 98 (95–100)
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was positive in two additional patients; in one neither dark
field microscopy nor serology was carried out, and in the
other serology was negative while dark field microscopy was
not carried out. Discrepancy analysis confirmed a T. pallidum
infection in both, in line with the clinical and anamnestic
information, resulting in a 100% concordance between the
TP-HD-HSV1/2 PCR and the resolved data. Of note, 5/19
(26%) of T. pallidum PCR-positive patients had a non-reactive
and 1/19 (5%) a low-reactive Venereal Disease Research
Laboratory test (VDRL) while Treponema pallidum particle
agglutination test (TPPA) was positive. Of these, three patients
had a positive IgM-ELISA that became negative after treatment,
two patients had a negative IgM-ELISA but a reactive VDRL
test at follow-up 8 and 9 days later, and one patient was
positive in the discrepancy analysis.
The TP-HD-HSV1/2 PCR was concordantly positive for
HSV-1 or HSV-2 in the seven patients who were diagnosed by
the reference methods. Two additional samples were HSV-1
positive by the TP-HD-HSV1/2 PCR. Discrepancy analysis
showed one to be false-positive; this patient had a candida
balanitis. It is assumed that the sample was cross-contaminated
during DNA extraction. The other was regarded as true-po-
sitive; this patient was clinically diagnosed with genital herpes
6 months before enrollment in our study. Despite a then
negative conventional HSV PCR, this diagnosis was made based
on the clinical picture, the recurrence of ulcers and the
cessation of symptoms after initiation of a suppressive antiviral
therapy. The current episode with three ulcers at one labium
majorum emerged after interruption of the suppressive
antiviral therapy and cleared after restart of this therapy,
substantiating the correct positive result of the TP-HD-HSV1/
2 PCR. H. ducreyi was not detected by the TP-HD-HSV1/2
PCR or the reference method in any specimens.
Overall sensitivity and specificity
The overall sensitivity and specificity of the TP-HD-HSV1/2
PCR was calculated to be 100% each for T. pallidum, 100% and
98% for HSV-1 and 100% and 98% for HSV-2 (Table 3). There
was no significant difference in the performance of the
TP-HD-HSV1/2 PCR compared with reference methods
(Tables 2, 3 and 5). Sensitivity and specificity could not be
calculated for H. ducreyi.
Treponema
pallidum
(n = 19)a
Herpes
simplex
(n = 8)a
Other
cause
(n = 10) p valueb
Age, mean years (SD) 42 (12) 43 (13) 40 (16) 0.95
Gender, male No. (%) 19 (100) 7 (88) 10 (100) 0.22
Site of ulcer, No. (%)
Genital region 17 (90) 8 (100) 10 (100) 0.71
Perianal region 1 (5) 1 (13) 0 (0) 0.46
Oral region 5 (26) 1 (13) 1 (10) 0.64
Incubation period
Median (IQR), days 30 (17–46) 12 (4–48) n.a. 0.13c
Data N/A, No. (%) 6 (32) 2 (25) n.a.
Duration of ulcers
Median (IQR), days 13 (7–19) 10 (3–14) 5 (1–10) 0.06
Data N/A, No. (%) 1 (5) 0 (0) 0 (0)
Ulcers per patient
Median number (IQR) 1 (1–3) 1 (1–2) 1 (1–1) 0.23
Multiple ulcers, No. (%) 8 (42) 3 (38) 1 (10) 0.21
Regional lymphadenopathy, No. (%) 14 (74) 4 (50) 2 (20) 0.06
Syphilis serology
VDRL
No. positive/No. performed (%) 10/16 (63) 1/3 (33) 0/4 (0) 0.08
Median titre (IQR) 1:4 (1:0–1:32) 1:0 (1:0–1:64) 1:0 (N/A) 0.05
IgM ELISA
No. positive/No. performed (%) 12/16 (75) 1/2 (50) 0/4 (0) 0.04d
Median titre (IQR) 2.14 (0.57–3.17) N/A (N/A) 0.22 (0.15–0.27) 0.06
TPPA
No. positive/No. performed (%) 18/18 (100) 2/8 (25) 2/10 (20) <0.001d,e
Median titre (IQR) 1:1280
(1:1280–1:5120)
1:0 (1:0–1:320) 1:0 (1:0–1:0) <0.001d, 0.003e
Dark field microscopy
No. positive/No. performed (%) 3/8 (38) 0/5 (0) 0/5 (0) 0.22
Conventional HSV PCR
No. positive/No. performed (%) 1/13 (8) 7/8 (88) 0/6 (0) 0.002e, 0.007f
Haemophilus ducreyi culture
No. positive/No. performed (%) 0/13 (0) 0/6 (0) 0/10 (0) 1
ELISA, enzyme-linked immune sorbent assay; HSV, herpes simplex virus; IgM, immunoglobulin M; IQR, interquartile
range; n.a., not applicable; N/A, not available; SD, standard deviation; TPPA, Treponema pallidum particle agglutination
test; VDRL, Venereal Disease Research Laboratory test.
aOne patient was co-infected with T. pallidum and HSV-2.
bIf not otherwise indicated, p values result from the Kruskal–Wallis test, ANOVA or Fisher’s exact test for comparison
between all groups. If p <0.05, pairwise comparison with adjustment for multiple comparison was done, and only p <0.05
of pairwise comparison are shown.
cWilcoxon rank sum test was performed due to two groups.
dT. pallidum vs. other cause. p value adjusted for groupwise multiple comparison.
eT. pallidum vs. herpes simplex. p value adjusted for groupwise multiple comparison.
fHerpes simplex vs. other cause. p value adjusted for groupwise multiple comparison.
TABLE 4. Characteristics of 36
patients with genital, anal
or oropharyngeal ulcers in
the prospective clinical study
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Discussion
We developed and evaluated the new TP-HD-HSV1/2 PCR for
laboratory diagnosis of genital, anal and oropharyngeal ulcers.
The primers and probes for T. pallidum and H. ducreyi were
novel, and the performance in testing for T. pallidum was
excellent (100% sensitivity and specificity). The primers
specific for HSV-1/2 were developed and successfully tested
by others on more than 3000 clinical specimens [21]. They
found a sensitivity of >99.5% for both serotypes, which is in
line with our results.
The TP-HD-HSV1/2 PCR was positive for T. pallidum in the
samples of six patients with negative (n = 5) or equivocal
(n = 1) VDRL. In three of these patients, the IgM-ELISA test
was positive, corroborating the suggested higher sensitivity of
a specific IgM test compared with the VDRL test in early
syphilis [11,30]. However, the IgM test was equivocal in one of
these patients and negative in two patients, which indicates
that in very early syphilis molecular methods such as our
TP-HD-HSV1/2 PCR may be superior to serology. The
TP-HD-HSV1/2 PCR was also accurate in samples from
oropharyngeal ulcers. These samples are not suitable for dark
field microscopy. However, the high frequency of unprotected
oral sex and the often underestimated rate of oral ulcers
caused by sexually transmitted pathogens [31] substantiate the
need for a PCR that reliably detects sexually transmitted
pathogens also in oropharyngeal ulcers [25,32]. The detection
of mixed infections by PCR in one patient of the present study
as well as in earlier trials [33,34] supports the usefulness of
PCR assays capable of a simultaneous and fast detection of
T. pallidum, HSV-1/2 and H. ducreyi in a patient. Previously
developed multiplex PCRs for these pathogens, including an
assay capable of the simultaneous detection of seven different
sexually-transmitted pathogens, are mostly conventional PCR
assays, which need time-consuming subsequent electrophore-
sis to detect PCR products (for example [35–39]). Only a few
multiplex real-time PCR assays have been developed [2,33,34],
and only two have been tested for their applicability in routine
clinical practice [33,34].
We sought to determine the rate of T. pallidum, HSV-1/2
and H. ducreyi in ulcers of our patients from Zurich,
Switzerland, and Graz, Austria. The proportion of 53% of
T. pallidum-positive patients in the present study appeared
higher than the rates of ulcers caused by syphilis reported
from other European areas, for example 2% in the UK [33],
3% in the Netherlands [3] or 35% in France [1]. Rates of
reported cases of T. pallidum infections vary across European
countries from <1 to 11/100 000 population in 2011, with an
overall decrease since 2002 [40]. In Switzerland, which is not
included in the above data from the European Centre for
Disease Prevention and Control, the rate of reported
T. pallidum infections was higher, with 12.4/100 000 in 2011
and an overall increase of 50% since 2006 [41]. This may have
contributed to the high rate of T. pallidum infections in our
patients. Another reason may be the higher male-to-female
ratio of 35:1 found here, as compared with other European
reports with a male-to-female ratio of 7:1 [1] or 1.5:1 [3]; as
ulcers inside the vagina often remain undetected, syphilis is
reported almost four times more often in men than in
women [40]. This skewed gender ratio might be due to the
exclusive recruitment of our patients in centres for derma-
tology or infectious diseases, whereas women with genital
ulcers usually see their gynaecologist.
HSV-1/2 was detected in 22% of our patients, and the rate
of HSV among ulcer patients reported by previous PCR studies
varied between 12.5% and 63% [33–37]. In previous decades,
genital herpes was primarily caused by HSV-2, but during the
current century, the proportion of HSV-1 as a causative agent
of genital herpes has increased in many developed countries
[42]. While recent studies from Africa and South America
report an HSV-2:HSV-1 ratio in the range of 10:1–20:1 in
TABLE 5. Cross-tabulation of the results of the new multiplex real-time PCR compared with the reference methods (resolved
data) in the clinical studya
New real-
time PCR
Treponema pallidumb Herpes simplex type 1b Herpes simplex type 2b
Reference method Reference method Reference method
Positive
No. (%)
Negative
No. (%)
Total
No. (%)
Positive
No. (%)
Negative
No. (%)
Total
No. (%)
Positive
No. (%)
Negative
No. (%)
Total
No. (%)
Positive 22c (100) 0 (0) 22 (56) 4 (100)d 1 (4) 5 (18) 5 (100) 0 (0) 5 (18)
Negative 0 (0) 17 (100) 17 (44) 0 (0) 23 (96) 23 (82) 0 (0) 23 (100) 23 (82)
Total 22 (100) 17 (100) 39 (100) 4 (100) 24 (100) 28 (100) 5 (100) 23 (100) 28 (100)
aAll numbers in the table refer to number of samples investigated, not patients.
bMcNemar test p 1.
cTwo of these samples were negative in the T. pallidum reference standard but positive for T. pallidum in the discrepancy analysis.
dOne of these samples was negative for herpes simplex type 1 in the reference standard and the discrepancy analysis, but medical history and disease course suggested a herpes
simplex infection.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O1020–O1027
CMI Glatz et al. PCR for genital, anal or oral ulcer disease O1025
favour of HSV-2 [34,36,37], one from the UK found a 1:1 ratio
[33] as we did.
The absence of H. ducreyi in our samples is in line with
European surveillance data from the last decade, reporting
H. ducreyi in 0.9–3% of ulcer patients from the Netherlands
[3] or France [1]. This low rate of chancroid in Europe
observed over the last 15 years is supposedly due to shifts
in social and public health conditions, such as improved
hygiene [43]. However, the development and availability of
an H. ducreyi-specific real-time PCR in Europe is useful for
several reasons. First, H. ducreyi is prevalent in many
geographical regions; for example, it is detected in up to
51% of patients with genital ulcers in Sub-Saharan Africa
[34,36,44] and travellers or immigrants from endemic
regions seen in industrialized countries might suffer from
chancroid [45,46]. Second, diagnostic tools other than PCR,
such as microscopy and cultivation, are not suitable for
routine clinical practice [15]. These insensitive techniques
would hamper the diagnosis of rare cases. To address these
issues in the United States, the Centers for Disease Control
and Prevention have recently developed a PCR assay for
H. ducreyi [2].
A limitation of the present study is that the HIV status of
patients was not known, which is due to restrictions of the
study protocol approved by the ethics committees in
Switzerland and Austria. Another limitation of our
TP-HD-HSV1/2 PCR is that other rare causes of genital,
anal or oropharyngeal ulcers (e.g. Chlamydia trachomatis
genotypes L1-L3, cytomegalovirus and Epstein-Barr virus) are
not included.
In conclusion, the TP-HD-HSV1/2 PCR proved to be
sensitive and specific for the detection of T. pallidum and
HSV-1/2 in patients with genital, anal or oropharyngeal ulcers.
This PCR is applicable in routine clinical practice and results
are available within 24 h after sampling. More patients with
suspected early T. pallidum infections but negative VDRL test
should be tested with the TP-HD-HSV1/2 PCR to confirm its
supposed SUPERIOR sensitivity compared with serology in
these types of specimens.
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